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Antibody responses to influenza vaccination in patients with
chronic renal failure. A bivalent type A inactivated influenza vi-
rus vaccine containing both sets of H3N2 and H,,N1 antigens
was given to patients with chronic renal failure and to control
subjects. The patients were divided into an azotemic group in
whom dialysis was not yet required and a hemodialyzed group.
Hemagglutination-inhibition (HI) antibody responses were mea-
sured at time intervals of 1, 3, and 4 weeks after vaccination. We
found that the mean postvaccination HI titers against both sets of
antigens in the patients as a group did not differ significantly from
those found in the control subjects as a group. The proportion of
responders showing a fourfold or greater increase in post-
vaccination antibody responses over prevaccination antibody
values for either set of antigens was similar in both groups of
patients and the group of control subjects. In general, an inverse
correlation was found between prevaccination antibody levels
and postvaccination antibody responses in both patients and
control subjects. The only exception to this trend was the re-
sponse of two of the azotemic patients to the H3N2 antigens who
failed to respond despite low prevaccination antibody levels.
These were the patients with the highest serum creatinine values.
Réponse immune a Ia vaccination anti-grippale chez les malades
atteints d'insuffisance rénale chronique. Un vaccin antigrippal,
bivalent, de type A, inactive, contenant a Ia fois des antigènes
H3N2 et H,,Nl a été administré a des malades atteints
d'insuffisance rénale chronique et a des témoins. Les malades
ont été divisés en un groupe pour lequel l'hemodialyse n'était
pas encore nécessaire et un groupe dialysé. L'hémagglutination-
inhibition (HI) a été mesurée a des intervailes de temps de 1, 3,
et 4 semaines apres Ia vaccination. Dans l'ensemble nous avons
constaté que les titres HI moyens postvaccinaux contre les deux
types d'antigenes n'étaient pas significativement différents chez
les malades par comparaison aux témoms. La proportion de ré-
ponses consistant en une augmentation de quatre fois ou plus du
titre d'anticorps par comparaison avec les valeurs prévaccinales
est similaire dans les deux groupes de malades et chez les con-
trbles. En general, une correlation inverse est trouvée entre les
taux d'anticorps prévaccinaux et Ia réponse postvaccinale it la
fois chez les malades et les contrôles. La seule exception a cette
tendance est Ia réponse nulle de deux sujets azotémiques aux
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antigènes H3N2 malgré des taux d'anticorps prévaccinaux
faibles. Ii s'agissait des malades dont les créatinines plasma-
tiques étaient les plus élevees.
Annual vaccination against influenza has been
recommended for individuals with chronic illnesses
[1, 2]. Before such a recommendation, however,
can be extended to patients with chronic renal fail-
ure, it is important to know how well they respond
to influenza vaccines. Jordan et al [3] found that
maintenance hemodialysis patients responded ade-
quately to inactivated influenza virus vaccines. In
another study, Pabico Ct al found that azotemic
nondialyzed patients had poorer antibody re-
sponses than did patients with nonazotemic renal
disease [4]. To obtain more information on antibody
responses to influenza antigens in patients with
chronic renal failure, we compared hemagglutina-
tion-inhibition (HI) antibody responses to an inacti-
vated bivalent influenza virus vaccine in non-
dialyzed azotemic patients, in patients treated with
maintenance hemodialysis, and in healthy controls.
The use of the inactivated bivalent vaccine contain-
ing A2/Victoriall975 (H3N2) and A/New Jersey!
1976 (H51Nl) viruses enabled us to study antibody
responses to a prevalent influenza virus (the former)
and to study those responses to a less prevalent one
(the latter, also known as swine flu virus).
Methods
Three groups of individuals took part in this
study, which was performed between December
1976 and January 1977. During that period, epidem-
ic influenza was not encountered in our community.
None of the participating individuals received corti-
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costeroid or immunosuppressive drugs for at least
12 months before investigation.
Control group. The control group consisted of 17
males, 40 to 63 years of age (mean age, 50.4), and 7
females, 42 to 53 years of age (mean age, 47.4).
They were hospital personnel who had normal renal
function as ascertained by normal urinalysis and
serum urea nitrogen and creatinine levels.
Azotemic patients. The azotemic-patient-group
consisted of 10 males, 33 to 65 years of age (mean
age, 53.1). Their mean serum urea nitrogen was 34
mgldl (range, 25 to 80), and their mean serum creati-
nine measured 3.9 mgldl (range, 1.9 to 8.3). Renal
failure was secondary to nephrosclerosis in 6 pa-
tients, chronic glomenilonephritis in 2, polycystic
kidney disease in 1, and diabetic nephropathy in 1.
All of these patients were clinically stable and did
not require dialytic therapy.
Hemodialyzed patients. The patient-group on
maintenance hemodialysis consisted of 19 men, 37
to 72 years of age (mean age, 53.5). Duration of he-
modialysis treatments varied from 1 week to 9 years
and 2 months (mean, 35.6 months). Renal failure
was caused by nephrosclerosis in 8 patients, chron-
ic glomerulonephritis in 4, polycystic kidney dis-
ease in 3, chronic interstitial nephritis in 3, and dia-
betic nephropathy in 1.
Study plan. Each subject received i.m. 0.5 ml of a
bivalent influenza virus vaccine containing 400
chicken cell agglutinin (CCA) units. Half was in
the form of A2/Victoriall975 virus (H3N2 anti-
gens), and the other half, A/New Jersey/1976 virus
(H1N1 antigens). The vaccine (produced by
Parke-Davis Co.) was that distributed by National
Influenza Vaccination Program of 1976. No adverse
reactions to the vaccine were encountered.
Sera samples were collected from the subjects be-
fore vaccination and at intervals of 1, 3, and 4
weeks after vaccination. We were unable to obtain
a complete set of serum specimens from two azo-
temic and two hemodialyzed patients. Serum sam-
ples were stored at —20° C. Prior to analysis, each
sample was treated with a standard receptor-de-
stroying enzyme (Microbiological Associates) to in-
activate any nonspecific inhibitors of hemagglutina-
tion [51. Subsequently, it was tested for specific
hemagglutination-inhibition activity against com-
mercially prepared A2/Aichi 2/1968 virus possess-
ing H3N2 antigens and A/New Jersey/1976 virus
possessing H1N1 antigens. The former virus is a
prototype of A2/Victoriail975 virus. Sera samples
were tested at an initial dilution of 1: 8 or higher.
Prevaccination antibody levels were expressed as
geometric mean hemagglutination-inhibition titers
in the form of log2 HI titer standard error of the
logarithm of the mean. In addition, postvaccination
antibody responses were expressed as multiples of
the initial prevaccination antibody levels in the form
of log2 x. For example, a fourfold postvaccination
antibody response is expressed as 2.0. The data
were evaluated by analysis of variance, correlation
between two variables, x2' and Student's t test.
Results
Antibody titers. The influenza antibody status of
our study population prior to vaccination is in
agreement with that reported previously for people
over 30 years of age [6]. The majority of the study
population had preexisting antibodies to the H3N2
and HSWINI antigens. Preexisting antibodies to the
H3N2 antigens were not observed in one azotemic
and one hemodialyzed patients. In addition, pre-
existing antibodies to the H1N 1 antigens were ab-
sent in five control, one azotemic, and one hemo-
dialyzed subjects.
Prevaccination antibody levels against the H3N2
antigens were significantly higher than were those
against H1Nl antigens in control (t = 6.22,
P < 0.01) and hemodialyzed subjects (t = 3.56
P < 0.01). In the nondialyzed azotemic patients,
however, prevaccination antibody titers against the
two sets of antigens were not statistically different
(t = 1.0, P = 0.0) (Table 1). In each group of sub-
jects, postvaccination antibody responses against
either sets of antigens obtained at intervals of 1, 3,
and 4 weeks after vaccination showed significant in-
creases when compared to prevaccination values.
Moreover, the three groups had similar post-
vaccination antibody responses at each interval. Fi-
nally, in the control group antibody titers of the
women were similar to those of the men.
Responses to the two sets of antigens in the vac-
cine. After vaccination, 55% of the study popu-
lation generated a fourfold or greater increase in HI
titer to the H3N2 antigens, whereas 90% showed a
comparable increase to the H1N1 antigens (Table
2). The proportion of responders showing such an
increase in titer was similar among the groups. In
addition, within each group, the geometric mean of
postvaccination increments in titers to the H1Nl
antigens was greater than was that to the H3N2 an-
tigens (Table 2).
In general, intensity of antibody response of our
subjects to the two sets of antigens was observed to
be inversely related to their prevaccination anti-
body levels (Table 2). The sole exception was the
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Table 1. Hemagglutination-inhibition (HI) titers following vaccination with inactivated influenza virus vaccine in patients with chronic
renal failure and in control individualsa
Viral antigens Groups
Serum HI titers"
Prevaccination
Postvaccination
I week 3 weeks 4 weeks PC
H3N2
HaW1NI
Azotemic
Hemodialyzed
Control
Azotemic
Hemodialyzed
Control
5.4 0.54 (10)
6.4 0.34 (19)
6.0 0.22 (24)
4.7 0.29 (10)
5.0 0.31 (19)
4.0 0.31 (24)
6.3 0.65 (10)
6.5 0.32 (18)
7.4 0.43 (24)
6.0 0.37 (10)
5.8 0.38 (18)
5.9 0.43 (24)
8.0 0.93 (8)
7.9 0.47 (17)
7.7 0.26 (24)
7.6 0.46 (8)
7.9 0.30 (17)
7.1 0.34 (24)
8.0 0.74 (8)
7.7 0.43 (18)
8.0 0.46 (24)
7.9 0.40 (8)
7.9 0.33 (18)
7.5 0.31 (24)
<0.05
< 0.05
< 0.01
<0.01
< 0.01
< 0.01
a Number of subjects are denoted in parentheses.
"Geometric mean HI titers are expressed as log2 HI titers standard errors of the logarithms of the means.
C Comparisons were among HI titers obtained prevaccination and at time intervals of 1, 3, and 4 weeks, respectively, after vaccination,
by a one-way analysis of variance.
Table 2. Antibody response to vaccination with inactivated influenza vaccine in patients with chronic renal failure and in control
individuals
Viral
antigens Groups
Proportions of
subjects showing
4-fold or
greater increase
in HI titers
Geometric means
of increments in
HI titers above
prevaccination
levelsa
Correlation coefficients
between prevaccination
antibody levels and
postvaccination
antibody responses P
H3N2 Azotemic
Hemodialyzed
Control
Total
6/10 (60%)
10/19 (53%)
13/24 (54%)
29/53 (55%)
2.4 0.56
1.6 0.37
2.0 0.32
+0.1163
—0.4654
—0.6255
>0.05
<0.05
<0.01
HSW,N1 Azotemic
Hemodialized
Control
Total
9/10 (90%)
17/19 (89%)
22/24 (92%)
48/53 (90%)
3.2 0.44
3.2 0.24
3.7 0.33
—0.7236
—0.4805
—0.5418
<0.01
<0.05
<0.01
Geometric means of fold-increases in titers above prevaccination levels are expressed as log2 x; that is, a difference between pre-
vaccination titer ar..J postvaccination response of 2.0 is equivalent to a fourfold increase.
response of the azotemic patients to the H3N2 anti-
gens. In these, there was no statistical relationship
between prevaccination antibody levels and post-
vaccination antibody responses. Finally, in the he-
modialyzed group, we found no correlation be-
tween postvaccination antibody responses and du-
ration of dialysis.
Effect of azotemia on antibody responses. To de-
termine whether severity of azotemia impaired anti-
body production, we examined the correlations
among serum creatinine values, prevaccination
antibody levels, and postvaccination antibody re-
sponses in the azotemic patients (Table 3 and Fig.
1). With regard to antibody production against the
H3N2 antigens, statistical analysis demonstrated
negative correlations between serum creatinine val-
ues and prevaccination antibody levels, as well as
between serum creatinine and postvaccination anti-
body responses. It should be noted, however, that
the significance of these correlations is uncertain
since there were only two patients with serum
creatinine values above 5 mg/dl, and both of these
failed to generate a fourfold antibody response to
the H3N2 antigens despite low prevaccination ti-
ters. Moreover, two additional patients with a
blunted response had serum creatinines below
5 mg/dl, but these had the highest prevaccination
antibody titers, which may have blunted the post-
vaccination response independently of the azotemic
state [6]. In any case, azotemia did not adversely
affect the antibody response to H21N1 antigens.
Table 3. Correlations among serum creatinine value,
prevaccination antibody level, and postvaccination antibody
response in azotemic patients
Correlation coefficients
Variables H3N2 H,N1
Serum creatinine and
prevaccination antibody level _0.6082a —0.1069
Serum creatinine and
postvaccination antibody response _O.6382a +0.1042
a Significant at P <0.05.
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Discussion
This study demonstrates that mean postvaccina-
tion antibody responses of azotemic and hemodial-
yzed patients following injection of an influenza
virus vaccine (H3N2 and H,1Nl antigens) were
comparable to those of individuals with normal
renal function. Our findings in hemodialyzed pa-
tients confirm those of Jordan et al [3], who showed
that when given a bivalent, type A and B influenza
virus vaccine, hemodialyzed patients were able to
produce serum HI antibody responses similar to
those of healthy subjects.
Although our azotemic patients as a whole pro-
duced antibodies against the two sets of influenza
antigens in a manner grossly similar to that of con-
trol subjects, our data, taken together with those of
Pabico et al [4], suggest that advanced azotemia
may selectively depress antibody responses to the
H3N2 antigens. In our two patients with the highest
serum creatinines, postvaccination antibody re-
sponse to the H3N2 antigens was markedly sup-
pressed (Fig. 1). Pabico et a! [4] found that of their
seven azotemic patients with serum creatinines
ranging from 2.3 to 14.1 mg/dl, only one showed a
fourfold or greater postvaccination antibody re-
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sponse against the H3N2 antigens. Note that all ex-
cept two of their patients had serum creatinines
above 5 mg/dl. Some of Pabico's patients, however,
were on corticosteroids or immunosuppressive drugs,
or both, and a different method of antibody deter-
mination was used.
Other studies on the effect of azotemia on anti-
body response to influenza vaccination in renal allo-
graft recipients have yielded conflicting results. For
example, Pabico et al observed that renal transplant
recipients having creatinine clearances of 70 mI/mm
or higher had a better response to influenza vaccina-
tion than did those with lower creatinine clearances
[7]. Other investigators, however, were unable to
detect any relationship between antibody response
and the severity of azotemia in similar patients
[8, 91. It is apparent that more studies are needed in
patients with advanced azotemia to clarify the po-
tential role of this state on the immunonogenicity of
the several influenza antigens.
Split-influenza virus vaccines, as used in the pres-
ent study, are reportedly less effective than whole
virus vaccines in eliciting antibodies in persons who
have not previously encountered the antigens in the
vaccines. Studies conducted by NIAID [6], how-
ever, demonstrated that in persons possessing anti-
bodies to influenza virus antigens prior to vaccina-
tion, both the split and whole virus vaccines are po-
tent in inducing antibody formation.
The number of patients used in the present study
was too small for evaluation of the protective ef-
fects of the vaccine. The mean HI titers reached by
our patients, however, are comparable to those
found to be protective by others [6]. With the ex-
ceptions noted above, our data suggest that both
azotemic and hemodialyzed patients do have the
ability to generate adequate antibody responses to
influenza vaccination.
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Fig. 1. Relationships between serum creatinine levels and serum
hemagglutination-inhibition (HI) antibody titers (both pre-
vaccination and postvaccination) in azotemic patients. For the
H3N2 antigens, significant negative correlations were demon-
strated between serum creatinine and prevaccination antibody
titers, as well as between serum creatinine and postvaccination
antibody responses. In the case of H,,N I antigens, no similar
correlations were found.
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